Baseline Characteristics of Patients Included in Present Analysis in Comparison to Excluded Patients and All DLBCL Patients Participating in PETAL Trial
| Characteristic | Patients included | Patients excluded | All patients |
|---|---|---|---|
| No. of patients | 449 | 160 | 609 |
| Median age (y) | 62 (range, 18–80) | 59.5 (range, 18–79) | 62 (range, 18–80) |
| Age > 60 y | 236 (52.6%) | 78 (48.8%) | 314 (51.6%) |
| Male sex | 249 (55.5%) | 93 (58.1%) | 342 (56.2%) |
| ECOG performance status ≥ 2 | 48 (10.7%) | 11 (6.9%) | 59 (9.7%) |
| Ann Arbor stage III or IV | 258 (57.5%) | 100 (62.5) | 358 (58.8%) |
| Extranodal sites > 1 | 148 (33.0%) | 50 (31.2%) | 198 (32.6%) |
| Lactate dehydrogenase > ULN | 257 (57.4%) | 78 (48.8%) | 335 (55.1%) |
| International Prognostic Index | |||
| Low risk | 160 (35.7%) | 64 (40.0%) | 224 (36.8%) |
| Low-intermediate risk | 111 (24.8%) | 47 (29.4%) | 158 (26.0%) |
| High-intermediate risk | 102 (22.8%) | 25 (15.6%) | 127 (20.9%) |
| High risk | 75 (16.7%) | 24 (15.0%) | 99 (16.3%) |
ECOG = Eastern Cooperative Oncology Group; ULN = upper limit of normal.
Data are given as number of patients affected, followed by percentage of total number of patients with documented data, unless otherwise noted.